1. Hyperostosis in Combination With Low Skull Density Ratio: A Potential Contraindication for Magnetic Resonance Imaging–Guided Focused Ultrasound Thalamotomy
- Author
-
Jason Yuen, Kai J. Miller, Bryan T. Klassen, Vance T. Lehman, Kendall H. Lee, and Timothy J. Kaufmann
- Subjects
VIM, ventral intermediate nucleus of the thalamus ,Medicine (General) ,R5-920 ,ET, essential tremor ,Brief Report ,DWI, diffusion-weighted imaging ,DTI, diffusion tensor imaging ,DBS, deep brain stimulation ,SDR, skull density ratio ,MRgFUS, MR imaging–guided focused ultrasound ,CT, computed tomography ,MR, magnetic resonance - Abstract
Since its approval in treating a number of movement disorders, magnetic resonance imaging–guided focused ultrasound (MRgFUS) has been adopted rapidly as one of the standard treatment modalities internationally. However, the efficiency of the energy delivered by the ultrasonic waves is largely determined by the highly variable bone morphology and density characteristics of the skull. One of the widely accepted indices used to facilitate patient selection is the skull density ratio (SDR). Earlier literature suggested that an SDR of less than 0.4 would be unfavorable for MRgFUS treatment. Some prior studies have excluded patients with hyperostosis. However, there is little published data regarding the impact of other skull features such as hyperostosis on treatment success. We present the case of a 66-year-old man with medically refractory essential tremor who had an SDR of 0.38 and extensive hyperostosis frontalis interna and underwent attempted MRgFUS thalamotomy treatment. However, intraoperatively the treatment was unsuccessful in generating sufficiently elevated temperature to create a lesion of the usual desired volume, and as expected, there was minimal clinical improvement. For comparison, we also summarize a case series of 4 other patients with an SDR of less than 0.4 who had successful outcomes. We believe that SDR should not be used as the only means of selecting patients for MRgFUS. Instead, important factors such as hyperostosis should be taken into consideration for patient selection and pretreatment counseling.
- Published
- 2021